- Structure-activity relationship study reveals ML240 and ML241 as potent and selective inhibitors of p97 ATPaseTsui Fen Chou
Division of Biology and Howard Hughes Medical Institute, California Institute of Technology, 1200 East California Boulevard, Pasadena, CA 91125, USA
ChemMedChem 8:297-312. 2013..Our results nominate ML240 as a promising starting point for the development of a novel agent for the chemotherapy of cancer, and provide a rationale for developing pathway-specific p97 inhibitors...
- Reversible inhibitor of p97, DBeQ, impairs both ubiquitin-dependent and autophagic protein clearance pathwaysTsui Fen Chou
Division of Biology, California Institute of Technology, Pasadena, CA 91125, USA
Proc Natl Acad Sci U S A 108:4834-9. 2011..DBeQ also potently inhibits cancer cell growth and is more rapid than a proteasome inhibitor at mobilizing the executioner caspases-3 and -7. Our results provide a rationale for targeting p97 in cancer therapy...
- Development of p97 AAA ATPase inhibitorsTsui Fen Chou
Division of Biology, California Institute of Technology, Pasadena, CA, USA
Autophagy 7:1091-2. 2011....
- Quantitative cell-based protein degradation assays to identify and classify drugs that target the ubiquitin-proteasome systemTsui Fen Chou
Division of Biology, California Institute of Technology, Pasadena, California 91125, USA
J Biol Chem 286:16546-54. 2011..Our work establishes a high-throughput screening-compatible pipeline for identification and classification of small molecules, cDNAs, or siRNAs that target components of the ubiquitin-proteasome system...